Neuca S.A. (NEU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neuca S.A. (NEU) has a cash flow conversion efficiency ratio of 0.074x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł89.73 Million ≈ $24.70 Million USD) by net assets (zł1.21 Billion ≈ $333.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neuca S.A. - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Neuca S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Neuca S.A. (NEU) total liabilities for a breakdown of total debt and financial obligations.
Neuca S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuca S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bain Capital Specialty Finance Inc
NYSE:BCSF
|
0.008x |
|
Sgis Songshan Co Ltd
SHE:000717
|
0.079x |
|
Hengsheng Energy Co Ltd
SHG:605580
|
0.057x |
|
Zhejiang Zanyu Technology Co Ltd
SHE:002637
|
0.028x |
|
New Huadu Supercenter Co Ltd
SHE:002264
|
0.016x |
|
IPERIONX LTD SP.ADR/10
F:30Z0
|
N/A |
|
Huadian Power International Corporation Limited
F:SHX
|
0.013x |
|
SHANDONG HI-SP.G.HD-0001
F:HRI
|
N/A |
Annual Cash Flow Conversion Efficiency for Neuca S.A. (2005–2024)
The table below shows the annual cash flow conversion efficiency of Neuca S.A. from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Neuca S.A. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł1.41 Billion ≈ $388.53 Million |
zł63.23 Million ≈ $17.40 Million |
0.045x | -83.57% |
| 2023-12-31 | zł1.06 Billion ≈ $290.96 Million |
zł288.27 Million ≈ $79.34 Million |
0.273x | -24.47% |
| 2022-12-31 | zł930.54 Million ≈ $256.10 Million |
zł335.94 Million ≈ $92.45 Million |
0.361x | +6.41% |
| 2021-12-31 | zł884.81 Million ≈ $243.51 Million |
zł300.20 Million ≈ $82.62 Million |
0.339x | -18.82% |
| 2020-12-31 | zł776.80 Million ≈ $213.79 Million |
zł324.67 Million ≈ $89.35 Million |
0.418x | +33.42% |
| 2019-12-31 | zł645.62 Million ≈ $177.68 Million |
zł202.25 Million ≈ $55.66 Million |
0.313x | +68.25% |
| 2018-12-31 | zł654.89 Million ≈ $180.23 Million |
zł121.94 Million ≈ $33.56 Million |
0.186x | -0.34% |
| 2017-12-31 | zł651.72 Million ≈ $179.36 Million |
zł121.76 Million ≈ $33.51 Million |
0.187x | -37.29% |
| 2016-12-31 | zł587.58 Million ≈ $161.71 Million |
zł175.05 Million ≈ $48.18 Million |
0.298x | -12.78% |
| 2015-12-31 | zł528.19 Million ≈ $145.37 Million |
zł180.40 Million ≈ $49.65 Million |
0.342x | -21.18% |
| 2014-12-31 | zł467.42 Million ≈ $128.64 Million |
zł202.56 Million ≈ $55.75 Million |
0.433x | +542.54% |
| 2013-12-31 | zł410.66 Million ≈ $113.02 Million |
zł27.70 Million ≈ $7.62 Million |
0.067x | -81.52% |
| 2012-12-31 | zł342.21 Million ≈ $94.18 Million |
zł124.92 Million ≈ $34.38 Million |
0.365x | -36.95% |
| 2011-12-31 | zł286.86 Million ≈ $78.95 Million |
zł166.08 Million ≈ $45.71 Million |
0.579x | +898.50% |
| 2010-12-31 | zł243.37 Million ≈ $66.98 Million |
zł14.11 Million ≈ $3.88 Million |
0.058x | -73.53% |
| 2009-12-31 | zł223.67 Million ≈ $61.56 Million |
zł48.99 Million ≈ $13.48 Million |
0.219x | +7.80% |
| 2008-12-31 | zł175.26 Million ≈ $48.23 Million |
zł35.61 Million ≈ $9.80 Million |
0.203x | -59.73% |
| 2007-12-31 | zł166.62 Million ≈ $45.86 Million |
zł84.07 Million ≈ $23.14 Million |
0.505x | +459.45% |
| 2006-12-31 | zł78.46 Million ≈ $21.59 Million |
zł-11.01 Million ≈ $-3.03 Million |
-0.140x | -173.54% |
| 2005-12-31 | zł69.16 Million ≈ $19.03 Million |
zł13.20 Million ≈ $3.63 Million |
0.191x | -- |
About Neuca S.A.
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company offers Rx, OTC drugs, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic an… Read more